Green Victoria L, Richmond I, Maguiness S, Robinson J, Helboe L, Adams I P, Drummond N S, Atkin S L
Department of Medicine, Wolfson Building, University of Hull, Cottingham Road, Hull HU6 7RX, UK.
Clin Endocrinol (Oxf). 2002 May;56(5):609-14. doi: 10.1046/j.1365-2265.2002.01521.x.
Somatostatin mediates its many inhibitory functions through five G-protein-coupled receptors (sstr1-5); however, it is not known whether somatostatin or its receptors are present in the endometrium.
We have used immunohistochemistry on formalin-fixed paraffin-embedded sections of normal human endometrium from the menstrual (n = 6), proliferative (n = 15) and secretory (n = 10) stages of the endometrial cycle to determine the pattern of expression of somatostatin receptor (sstr) subtype 2. In addition, we have used quantitative polymerase chain reaction (PCR) to determine the level of expression of the sstr2 mRNA in 17 samples of normal human endometrium.
Endometrial tissue had been removed from patients undergoing dilation and curettage (D&C) for menorrhagia and had been determined to be normal histologically.
Immunostaining in the epithelium, endothelium and the stroma of the endometrial sections was characterized and was scored positive or negative. The PCR results were analysed using the software provided to standardize the expression of sstr2 against that of constitutively expressed beta-glucoronidase in the same sample. A final percentage value of the level of sstr2 expression was then determined.
sstr2 was expressed variably throughout all the stages of the menstrual cycle in the epithelium, the endothelium and the stroma. In particular, the position of sstr2 expression varied in the epithelial cells surrounding the endometrial glands from being basal or diffuse in the proliferative and secretory phase to being lumenal in the menstrual stage. Quantitative PCR showed that 15 of 17 samples expressed sstr2 mRNA and the level of expression between individual samples varied dramatically.
These data show that sstr2 is present in the endometrium and its location seems to vary through the menstrual cycle.
生长抑素通过五种G蛋白偶联受体(sstr1 - 5)介导其多种抑制功能;然而,子宫内膜中是否存在生长抑素或其受体尚不清楚。
我们采用免疫组织化学方法,对来自子宫内膜周期月经期(n = 6)、增殖期(n = 15)和分泌期(n = 10)的正常人类子宫内膜福尔马林固定石蜡包埋切片进行检测,以确定生长抑素受体(sstr)2型亚型的表达模式。此外,我们使用定量聚合酶链反应(PCR)来测定17份正常人类子宫内膜样本中sstr2 mRNA的表达水平。
子宫内膜组织取自因月经过多接受刮宫术(D&C)的患者,经组织学检查确定为正常。
对子宫内膜切片的上皮、内皮和基质中的免疫染色进行特征描述,并评定为阳性或阴性。使用提供的软件分析PCR结果,以标准化同一样本中sstr2相对于组成性表达的β - 葡萄糖醛酸酶的表达。然后确定sstr2表达水平的最终百分比值。
sstr2在月经周期的所有阶段,在上皮、内皮和基质中均有不同程度的表达。特别是,子宫内膜腺体周围上皮细胞中sstr2的表达位置有所变化,从增殖期和分泌期的基底或弥漫性表达变为月经期的腔面表达。定量PCR显示,17个样本中有15个表达sstr2 mRNA,各个样本之间的表达水平差异很大。
这些数据表明sstr2存在于子宫内膜中,其位置似乎在月经周期中有所变化。